Somagenetix
https://www.wysszurich.ch/projects/somagenetix
8952 Schlieren, Wagistrasse 23
Gene therapy solutions for patients with severe inherited diseases.
Somagenetix
Wagistrasse 23
8952 Schlieren
47 Ergebnisse für "immunotherapies" unter Somagenetix
Development of a novel class of interleukin-2 immunotherapies for m...
... immunotherapies for metastatic cancer. Swiss Medical Weekly, 149:w14697. Copy Abstract Tumour immunotherapy, and ... Development of a novel class of interleukin-2 immunotherapies for metastatic cancer - Zurich Open ... Development of a novel class of interleukin-2 immunotherapies for metastatic cancer - Zurich Open ... Development of a novel class of interleukin-2 immunotherapies for metastatic cancer - Zurich Open ...
Emerging immunotargets and immunotherapies in prostate cancer - Zur...
... Emerging immunotargets and immunotherapies in prostate cancer - Zurich Open Repository and Archive ... Emerging immunotargets and immunotherapies in prostate cancer - Zurich Open Repository and Archive ... Emerging immunotargets and immunotherapies in prostate cancer - Zurich Open Repository and Archive ...
ETH Zürich - Feasibility Lab
Technoparkstrasse 1
8005 Zürich
25 Ergebnisse für "immunotherapies" unter ETH Zürich - Feasibility Lab
Meet Dr Rodrigo Vazquez-Lombardi working on engineered cellular imm...
... Meet Dr Rodrigo Vazquez-Lombardi working on engineered cellular immunotherapies Meet Dr Rodrigo ... Vazquez-Lombardi working on engineered cellular immunotherapies The Peruvian-Australian researcher ... Meet Dr Rodrigo Vazquez-Lombardi working on engineered cellular immunotherapies – Department of ... Meet Dr Rodrigo Vazquez-Lombardi working on engineered cellular immunotherapies – Department of ... Meet Dr Rodrigo Vazquez-Lombardi working on engineered cellular immunotherapies – Department of ...
Meet Dr Rodrigo Vazquez-Lombardi working on engineered cellular imm...
... Meet Dr Rodrigo Vazquez-Lombardi working on engineered cellular immunotherapies Meet Dr Rodrigo ... Vazquez-Lombardi working on engineered cellular immunotherapies The Peruvian-Australian researcher ... Meet Dr Rodrigo Vazquez-Lombardi working on engineered cellular immunotherapies – Laboratory for ... Meet Dr Rodrigo Vazquez-Lombardi working on engineered cellular immunotherapies – Laboratory for ... Meet Dr Rodrigo Vazquez-Lombardi working on engineered cellular immunotherapies – Laboratory for ...
ETH Zürich - Numerische Materialmodellierung
8005 Zürich, Technoparkstrasse 1 / Einstein PFA G 11 (2. OG)
ETH Zürich - Numerische Materialmodellierung
Technoparkstrasse 1
8005 Zürich
20 Ergebnisse für "immunotherapies" unter ETH Zürich - Numerische Materialmodellierung
A path forward to improving the specificity of immunotherapies - Re...
... A path forward to improving the specificity of immunotherapies - Research Collection ... A path forward to improving the specificity of immunotherapies - Research Collection Header Upper ... A path forward to improving the specificity of immunotherapies - Research Collection ...
Robert Koch Award 2017 for Antonio Lanzavecchia | ETH Zurich
... immunotherapies. 10.07.2017 by Dominic Dähler Prof. Antonio Lanzavecchia ... the hope of better vaccines and more effective immunotherapies. Fundamental studies of the highly ... their ground-breaking contributions on the development of new vaccines and immunotherapies. 10.07.2017 ... Lanzavecchia, this was always associated with the hope of better vaccines and more effective immunotherapies ...
ImmunOs Therapeutics AG
http://immunostherapeutics.com/
8952 Schlieren, Wagistrasse 14
ImmunOs Therapeutics AG is a clinical-stage biotechnology company developing the next generation of novel immunotherapies that enhance the efficacy of market leading checkpoint inhibitors and costimulatory agonists for cancer therapy. The company is actively discussing and exploring new strategic collaborations with leading global pharmaceutical companies.
ImmunOs Therapeutics AG
Wagistrasse 14
8952 Schlieren
10 Ergebnisse für "immunotherapies" unter ImmunOs Therapeutics AG
ENGAGING THE ENTIRE IMMUNE SYSTEM TO FIGHT DISEASE - Immunostherapy
... generation of novel immunotherapies that will improve the lives of patients with serious diseases. ... generation of novel immunotherapies that will improve the lives of patients with serious diseases. LeaRN More ... PIPELINE ImmunOs’ HLA-based pipeline includes first-in-class immunotherapies for the treatment of cancer ...
CDR-Life AG
8810 Horgen, Tödistrasse 46
CDR-Life is a Zurich-based biotech company that discovers and develops innovative medicines for the treatment of high need diseases. We invent and develop therapeutic antibody fragments with a focus on immuno-oncology and ophthalmology.
CDR-Life AG
Tödistrasse 46
8810 Horgen
8 Ergebnisse für "immunotherapies" unter CDR-Life AG
... of novel immunotherapies in patient biopsies ZURICH, Switzerland, May 23, 2018 – CDR-Life inc. has ... technology. The collaboration will use synergies between the modular multispecific immunotherapies from CDR ... of novel immunotherapies in patient biopsies ZURICH, Switzerland, May 23, 2018 – CDR-Life inc. has ... technology. The collaboration will use synergies between the modular multispecific immunotherapies from CDR ...
News – CDR-Life
... ETH Zürich Ex vivo drug response profiling of novel immunotherapies in patient biopsies Download Press ... will use synergies between the modular multispecific immunotherapies from CDR-Life and the ... profiling of novel immunotherapies in patient biopsies Download Press Release (PDF) ZURICH, Switzerland, May ... modular multispecific immunotherapies from CDR-Life and the pharmacoscopy technology from the Snijder ...
Virometix AG
8952 Schlieren, Wagistrasse 14
+41 (0)43 433 86 60
info@virometix.com
Virometix AG is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases.
Virometix AG
Wagistrasse 14
8952 Schlieren
4 Ergebnisse für "immunotherapies" unter Virometix AG
... , Switzerland, towards the evaluation of nanoparticle-based cancer vaccines and immunotherapies ... vaccine targets and immunotherapies • Mammalian cell culture and experience with cancer cell lines ... , Switzerland, towards the evaluation of nanoparticle-based cancer vaccines and immunotherapies ... vaccine targets and immunotherapies • Mammalian cell culture and experience with cancer cell lines ...
... evaluation of nanoparticle-based cancer vaccines and immunotherapies as part of a bigger team of biologists ... tests and experiments for the functional validation of novel cancer vaccine targets and immunotherapies ... evaluation of nanoparticle-based cancer vaccines and immunotherapies as part of a bigger team of biologists ... tests and experiments for the functional validation of novel cancer vaccine targets and immunotherapies ...
Repertoire Immune Medicines (Switzerland) AG
8952 Schlieren, Wagistrasse 27
The key to our strategy lies in understanding the inner workings of the immune synapse – the interaction between the T cell and the antigen presenting cell which dictates the immune code that tells a T cell to become toxic and to kill the infected tissue. Our scientists created and developed the DECODETM and DEPLOY suite of technologies, which allows in-depth characterization of TCR-antigen pairings – and the ability to rationally design and clinically develop targeted immune medicines. Our scientists also have developed novel technologies that attach potent immunomodulators to T cells, enabling us to deliver potent cytokines such as IL-15 or IL-12 directly to tumors by using the natural homing power of the T cells to traffic to diseased tissue.
Repertoire Immune Medicines (Switzerland) AG
Wagistrasse 27
8952 Schlieren
1 Ergebnisse für "immunotherapies" unter Repertoire Immune Medicines (Switzerland) AG
Jan Kisielow, PhD • Repertoire Immune Medicines
... provide the basis for personalized immunotherapies. He earned his PhD in cell biology from the Basel ... antigenic reactivity of T cells to provide the basis for personalized immunotherapies. He earned his PhD in ...
University of Zurich
https://www.campus-schlieren.uzh.ch/en.html
8952 Schlieren, Wagistrasse 12
The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.
University of Zurich
Wagistrasse 12
8952 Schlieren
29 Ergebnisse für "immunotherapies" unter University of Zurich
UZH - UZH Innovation Hub - UZH spin-off Anaveon successfully closed...
... . based in the a UK. Anaveon works on a new approach for developing immunotherapies for cancer. The ... approach for developing immunotherapies for cancer. The technology was developed by Prof. Onur Boyman. The ...
UZH - Institute for Regenerative Medicine • IREM - Antibody-based R...
... immunotherapies for neurodegenerative diseases, including Aducanumab resulting from research conducted at the ... Regeneration With the advent of clinically effective immunotherapies for neurodegenerative diseases, including ...
Roche Glycart AG
https://www.roche.ch/en/sites/schlieren
8952 Schlieren, Wagistrasse 10
+41 43 215 10 00
The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.
Roche Glycart AG
Wagistrasse 10
8952 Schlieren
28 Ergebnisse für "immunotherapies" unter Roche Glycart AG
Roche | Ovarian cancer treatment advances over time – what’s next?
... . The introduction of immunotherapies, and combinations of immunotherapies with other targeted therapies ... to see in the treatment of this deadly cancer. The introduction of immunotherapies, and combinations ... of immunotherapies with other targeted therapies, are also expected to come through in this disease ...
Roche - Immunotherapy at Roche
... . Cancer immunotherapies of the past In fact, the idea of harnessing the immune system to fight cancer is a ... generate positive results. Unlike earlier immunotherapies, these drugs work by targeting a specific set of ... . Cancer immunotherapies of the past In fact, the idea of harnessing the immune system to fight cancer is a ... generate positive results. Unlike earlier immunotherapies, these drugs work by targeting a specific set of ...
CSEM Zurich SA
8005 Zürich, Technoparkstrasse 1 / Zeppelin 5011
+41 44 497 14 11
zurich@csem.ch
The Centre Suisse d'Electronique et de Microtechnique (CSEM) is a national innovation accelerator—a catalyst for the transfer of technologies and know-how from fundamental research to industry.
CSEM Zurich SA
Technoparkstrasse 1
8005 Zürich
8 Ergebnisse für "immunotherapies" unter CSEM Zurich SA
Personalized drug discovery at lightspeed
... novel immunotherapies for the treatment of cancer and autoimmune diseases. A new paradigm is emerging ... immunotherapies for each patient in cancers and autoimmune diseases HiFiBiO Therapeutics, a multinational ... will enable novel immunotherapies for the treatment of cancer and autoimmune diseases. A new paradigm ... patient. Curative immunotherapies for each patient in cancers and autoimmune diseases HiFiBiO Therapeutics ...
Personalized drug discovery at lightspeed
... novel immunotherapies for the treatment of cancer and autoimmune diseases. A new paradigm is emerging ... immunotherapies for each patient in cancers and autoimmune diseases HiFiBiO Therapeutics, a multinational ... and manufacture single-cell microfluidics that will enable novel immunotherapies for the treatment of ... from patient to patient. Curative immunotherapies for each patient in cancers and autoimmune diseases ...
